<DOC>
	<DOCNO>NCT00209989</DOCNO>
	<brief_summary>The purpose study determine efficacy determination Time To Progression ( TTP ) patient resectable GBM non surgical GBM size le 5 cm treat combination ZARNESTRA plus Radiation therapy .</brief_summary>
	<brief_title>Phase II Trial Assess Radiosensitizing Effect ZARNESTRA Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Patients must pathologically confirm ( histology cytology ) , resectable non resectable , glioblastoma multiforme size &lt; 5 cm MRI non resectable Patients must least 7 day 2 month since surgery biopsy . Patients must ECOG Performance Status â‰¤ 2 . Patients must age 18 Patient sign informed consent form Patients unresectable glioblastoma size &gt; 5 cm MRI Patients clinically apparent leptomeningeal metastases Patients uncontrolled seizure despite standard anticonvulsant therapy Any prior systemic treatment ( chemotherapy , immunotherapy , hormonal therapy ) glioblastoma multiforme Significantly abnormal haematological status judge : Absolute neutrophil count ( ANC ) &lt; 1500/mm3 ( 1.5*109/l ) Platelet count &lt; 100,000/mm3 ( 100*109/l ) Serum bilirubin &gt; 2 mg/dl ( &gt; 34 mmol/l ) Transaminase &gt; 2.5x upper limit institutional normal Creatinine &gt; 1.5 mg/dl ( &gt; 132 mmol/l ) Inability cooperate treatment protocol Patients undergo image evaluation Participation investigational drug trial 30 day prior selection Pregnant nursing mother . ( Female patient childbearing potential must use adequate contraception . ) Any malignancy within past five year . Exceptions : superficial basal cell carcinoma nonmetastatic squamous cell cancer skin , cervix cancer ( cervical intraepithelial neoplasia CIN FIGO stage 1 ) prostate intraepithelial neoplasia ( PIN ) , biochemical relapse free least 3 year . Any prior systemic chemotherapy past five year malignancy medical history Any concurrent disease opinion investigator would constitute hazard participate study Known sensitivity imidazole derivatives Patients law protection Medical history phlebitis pulmonary embolism , thrombocytosis , myocardiopathy , relevant cardiac pathology ( auricular flutter , auricular fibrillation ) Medical history immunoallergic pneumopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Zarnestra</keyword>
	<keyword>Radiation therapy</keyword>
</DOC>